Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The acquisition of SPR Therapeutics will allow Medtronic to expand its portfolio of neuromodulator medical devices. The deal is expected to close in 2027.
These third-party marketers earn commissions from their insurer clients not only upon initial signups but also every time “their” enrollees renew without changing plans.
The agency cited free speech as its reasoning for rescinding the long-standing policy. While in place, the rule barred companies that agreed to settlements with the Securities and Exchange Commission from publicly denying allegations made by regulators.
RadNet Chaiman and CEO Howard Berger, MD, explains why the company has invested tens of millions into DeepHealth to rapidly build up a new business model.
The company made the changes after its manufacturer rebates for insulin were challenged by the Federal Trade Commission. Among other shifts, Optum said 100% of all rebates will be distributed to customers by 2028.
Some of the claims in the lawsuit, brought against Novant Health by Kyle Horton, MD, are backed by a report from the North Carolina Department of Health and Human Services.
The agencies said private equity firms are rolling up healthcare sectors through serialized purchases that fly under the radar of regulators, creating an unsustainable level of consolidation.
A new report from the Office of the Inspector General found the FDA failed to properly record meetings with drug manufacturers, ultimately approving drugs later shown to have safety and efficacy issues.
The integration was announced during the annual JP Morgan Health Care Conference in San Francisco. The program works through Amazon Benefits Manager to remotely help patients with weight and blood pressure management.
The drug Caplyta, owned by Intra-Cellular Therapies, is being used to treat bipolar disorder and schizophrenia. In 2024, it brought in more than $481 million in sales.